NEWSROOM
Press Releases by Agendia
News
Press Releases
Three New Studies Presented at ASCO Annual Meeting Demonstrate Benefits of MammaPrint in Aiding Individualized Treatment Management for Early-Stage Breast Cancer Patients
A multi-center trial demonstrated that MammaPrint identified 30% more low risk patients than the 21-gene test. MammaPrint Low Risk patients had an excellent 98.9% 5-year metastasis free survival Data from the I-SPY 2 trial reported Read More
Agilent Technologies and Agendia Sign Agreement on Molecular Cancer Diagnostics
Agreement Accelerates the Development of Tests to Help Assess Risk of Disease Recurrence in Women with Early-Stage Breast Cancer SANTA CLARA, Calif., IRVINE Calif., June 2, 2017-Agilent Technologies Inc. (NYSE: A) and Agendia, Inc. today Read More
Agendia’s MammaPrint Now Included in Blue Shield of California Coverage for Breast Cancer Patients
IRVINE, CA and AMSTERDAM – 1 June 2017 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announces that Blue Shield of California has updated its Medical Policy 2.04.36 Assays Read More
Agendia’s MammaPrint Now Included in First Coast Coverage for Medicare Breast Cancer Patients in Florida, Puerto Rico and the Virgin Islands
IRVINE, CA and AMSTERDAM – 2 May 2017 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announces that First Coast Service Options Inc. (“First Coast”), the Medicare contractor for Read More
Agendia Appoints Patrick J. Balthrop Sr., Former CEO of Luminex, as Chairman
IRVINE, CA and AMSTERDAM – 12 April 2017 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announces the appointment of Patrick J. Balthrop Sr., former CEO of Luminex, as Read More
European Group on Tumour Markers (EGTM) Updated Guidelines Recommend Agendia’s MammaPrint Test with Highest Level 1A Clinical Evidence
MammaPrint® is the first and only multigene test to receive level 1A status, based on prospective, randomized data from the MINDACT trial IRVINE, CA and AMSTERDAM, 21 March 2017 – Agendia, a world leader in Read More
German Gynecological Oncology Group (AGO) Acknowledges MammaPrint in Breast Cancer Guidelines as Having Level 1A Clinical Evidence
2017 Guidelines of the AGO Breast Committee acknowledges Agendia’s MammaPrint test with highest medical evidence level 1A for identification of patient subgroups who can potentially forgo chemotherapy for breast cancer IRVINE, CA and AMSTERDAM – Read More
